[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. - July 27, 2022 -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced it will give a poster presentation at the annual Alzheimer’s Association International Conference (AAIC®) to be held July 31-August 4, 2022 at the San Diego Convention Center, San Diego California and online.

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 8th, 2022 – ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has received final approval from The Nasdaq Capital Market LLC (“Nasdaq”) to list its common shares (the “Common Shares”) on Nasdaq. The Company’s Common Shares will begin trading on Friday, July 8th, 2022, under the symbol “PMN”.

[PRESSWIRE] Santiago de Compostela, Spain - July 04, 2022 -- Libera Bio announced today that it has closed its Seed Round to advance its MPN Technology® into enabling studies and towards the clinic.

[PRESSWIRE] Austria - 04.07.22 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of research results demonstrating that the commonly used anti-histamine, azelastine, is a potent inhibitor of major variants of SARS- CoV-2 in the peer-reviewed journal Frontiers in Pharmacology (1).

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – June 22, 2022 - ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, is pleased to announce that it has entered into debenture amendments with seven (7) creditors to settle an aggregate of US$7,000,000 of indebtedness via the issuance of 70,000,000 Series 1 Preferred Shares ("Series 1 Shares") of the Company at US$0.10 per share.

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – June 22, 2022 – ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has filed a registration statement on Form 10 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC") to register the Company's common shares (the "Common Shares") under Section 12(b) of the Securities Exchange Act of 1934, as amended, in connection with its application to list its Common Shares on the Nasdaq Capital Market (“Nasdaq”).

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – June 22, 2022 – ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has amended its articles to authorize the issuance of 70,000,000 Series 1 Preferred Shares (“Series 1 Shares”) which it intends to use in settlement of its outstanding debentures.

[PRESSWIRE] London, UK - 13 June 2022 -- Datar Cancer Genetics has announced its partnership with U.K. based The Cancer Screening Trust to offer its innovative, blood-based, cancer screening Trucheck solution. Datar Cancer Genetics has been at the forefront in developing greater insight into the cancer ecosystem and offering its innovative oncology focussed services to clinicians and patients globally.

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, MA —May 17, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation at the Neuro4D International Conference, held at the Atrium Hotel, Mainz, Germany, May 16-17^th.

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 13, 2022 – There was an error at the end of the first paragraph.  March 31, 2021 has been changed to March 31, 2022.  There were no other changes to the release.  Please find full corrected release below.